Free Trial

Biofrontera (BFRI) Stock Price, News & Analysis

+0.02 (+1.79%)
(As of 05/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
48,565 shs
Average Volume
532,502 shs
Market Capitalization
$5.80 million
P/E Ratio
Dividend Yield
Price Target

Biofrontera MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
1,478.9% Upside
$18.00 Price Target
Short Interest
0.75% of Float Sold Short
Dividend Strength
News Sentiment
0.10mentions of Biofrontera in the last 14 days
Based on 5 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($3.21) to ($0.23) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.24 out of 5 stars

BFRI stock logo

About Biofrontera Stock (NASDAQ:BFRI)

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

BFRI Stock Price History

BFRI Stock News Headlines

Biofrontera Inc. (NASDAQ:BFRI): Is Breakeven Near?
See More Headlines
Receive BFRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$34.07 million
Book Value
($1.06) per share


Free Float
Market Cap
$5.80 million
No Data
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Hermann Luebbert Ph.D. (Age 68)
    CEO, President & Executive Chairman
    Comp: $733.23k
  • Mr. Eugene Frederick Leffler III (Age 39)
    Chief Financial Officer
    Comp: $378.58k
  • Ms. Erica F. Gates CPA
    M.B.A., Senior Director of Finance & Principal Accounting Officer
  • Mr. Jon Lyons M.B.A.
    Ph.D., Vice President of Scientific & Medical Affairs
  • Ms. Alycia Torres
    Vice President of Administration
  • Mr. Daniel Hakansson J.D.
    General Counsel & Head of Compliance
  • Ms. Samantha Widdicombe
    Senior Director of Strategic Accounts & Communications
  • Mr. Mark Baldyga
    Vice President of Sales & Marketing

BFRI Stock Analysis - Frequently Asked Questions

Should I buy or sell Biofrontera stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biofrontera in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BFRI shares.
View BFRI analyst ratings
or view top-rated stocks.

What is Biofrontera's stock price target for 2024?

1 Wall Street research analysts have issued twelve-month target prices for Biofrontera's shares. Their BFRI share price targets range from $18.00 to $18.00. On average, they predict the company's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 1,478.9% from the stock's current price.
View analysts price targets for BFRI
or view top-rated stocks among Wall Street analysts.

How have BFRI shares performed in 2024?

Biofrontera's stock was trading at $2.77 at the beginning of 2024. Since then, BFRI stock has decreased by 58.8% and is now trading at $1.14.
View the best growth stocks for 2024 here

When is Biofrontera's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024.
View our BFRI earnings forecast

How were Biofrontera's earnings last quarter?

Biofrontera Inc. (NASDAQ:BFRI) announced its quarterly earnings data on Friday, March, 15th. The company reported ($2.33) EPS for the quarter. The firm earned $10.60 million during the quarter. Biofrontera had a negative net margin of 69.44% and a negative trailing twelve-month return on equity of 1,390.99%.

When did Biofrontera's stock split?

Biofrontera's stock reverse split before market open on Wednesday, July 5th 2023. The 1-20 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Biofrontera IPO?

Biofrontera (BFRI) raised $19 million in an initial public offering on Friday, October 29th 2021. The company issued 3,100,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company acted as the underwriters for the IPO.

Who are Biofrontera's major shareholders?

Biofrontera's stock is owned by a number of retail and institutional investors. Top institutional investors include Rosalind Advisors Inc. (9.91%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Biofrontera?

Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BFRI) was last updated on 5/23/2024 by Staff

From Our Partners